Satya B. Das, MD, MSCI (Medical Oncology)Lead of the Neuroendocrine Tumor and PRRT Programs
Assistant Professor of Medicine
Dr. Satya Das’ areas of expertise include neuroendocrine cancer and early phase drug development across the spectrum of gastrointestinal malignancies. His research interests focus on designing studies for patients with NETs and NECs, utilizing the impairment of DNA damage repair to create new treatment strategies for gastrointestinal cancers and assessing when to optimally sequence PRRT. Clinically, Dr. Das takes care of patients with advanced GI malignancies however NET patients make up more than 60% of Dr. Das’s practice.
Dr. Das is the lead of the neuroendocrine tumor program and PRRT program at Vanderbilt. He serves on the NCCN Neuroendocrine and Adrenal Tumors Guidelines Panel, the National Cancer Institute Neuroendocrine Tumor Task Force, the Continuing Education Committee of NANETs and the ECOG Neuroendocrine Tumor Working Group.
Hear Dr. Das speak about the impact of PRRT, peptide receptor radionuclide therapy, in patients with well-differentiated neuroendocrine tumors: https://www.cancernetwork.com/view/satya-das-md-msci-on-the-impact-of-prrt-in-patients-with-well-differentiated-nets
Dr. Das’ administrative assistant is Ashley Cunningham and she can be reached at 615-343-6653.